SITC 2019 – Development of a natural killer (NK) Immunograft® platform for the evaluation of the pharmacodynamics of immuno-oncology therapeutics
Development of a natural killer (NK) Immunograft® platform for the evaluation of the pharmacodynamics of immuno-oncology therapeutics
BhBhavna Verma1, Bruce Ruggeri1, Jon Weidanz2, and Amy Wesa1
1Champions Oncology, Rockville, MD, USA. 2Abexxa, Biologics, Arlington, TX, USA.
Harnessing NK cell anti-cancer cytotoxicity has gained interest as a therapeutic strategy, and consequently improved preclinical models supporting the translation of NK cell–mediated therapies to the clinic are desired. Reproducible models with human NK engraftment into immunodeficient mice co-engrafted with cell line-derived xenograft or patient-derived xenograft tumor models have been lacking due to an inability to support NK cell engraftment and persistence. Here we evaluated IL-15-NOG mice for the engraftment and sustained survival of both ex vivo expanded and primary human NK cell isolates for establishing models that engraft effectively with both human NK cells and a PDX or CDX tumor.